

BIO-PATH HOLDINGS INC
Form 8-K
July 30, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 29, 2010

BIO-PATH HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

| | | |
|-----------------------------------------------------------|---------------------------------------|----------------------------------------------------|
| Utah (State or other jurisdiction of incorporation) | 000-53404 (Commission File Number) | 87-0652870 (IRS Employer Identification No.) |
|-----------------------------------------------------------|---------------------------------------|----------------------------------------------------|

| | |
|--------------------------------------------------------------------------------------|---------------------|
| 3293 Harrison Blvd., Ste. 220, Ogden, UT (Address of principal executive offices) | 84403 (Zip Code) |
|--------------------------------------------------------------------------------------|---------------------|

801-399-5500
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On July 29, 2010, Bio-Path Holdings, Inc. issued a press release titled “Bio-Path Holdings Announces Dosing of First Patient in a Phase I Clinical Trial of Its Liposomal Grb-2 Cancer Drug Candidate.” A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit Number | Description |
|-------------------|------------------------------------|
| 99.1 | Press Release dated July 29, 2010. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-PATH HOLDINGS, Inc.

Dated: July 29, 2010

By: /s/ Peter H. Nielsen
Peter H. Nielsen
President and Chief Executive Officer

EXHIBIT INDEX

| Exhibit Number | Description |
|-------------------|------------------------------------|
| 99.1 | Press Release dated July 29, 2010. |
